What are PDE4 inhibitor drugs?

PDE4 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting PDE4). 0 are currently marketed, with 22 more in clinical development.

PDE4 inhibitor

0 marketed 18 in Phase 3 2 in Phase 2 2 in Phase 1

This page covers all PDE4 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PDE4.

Targets

PDE4

Phase 3 pipeline (18)

LAS41008 · Almirall, S.A. · Immunology
LAS41008 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
MT1013 · Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Immunology
MT1013 is a small molecule that targets the PDE4 enzyme.
vehicle of LAS41007 · Almirall, S.A. · Respiratory
LAS41007 is a small molecule inhibitor of the PDE4 enzyme.
crisaborole ointment · Pfizer · Dermatology
Crisaborole inhibits phosphodiesterase 4 (PDE4), leading to increased levels of cyclic AMP (cAMP) which has anti-inflammatory effects.
PF-06947386 · Pfizer · Immunology
PF-06947386 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory signaling by increasing intracellular cAMP levels.
LASW1835 · Almirall, S.A. · Respiratory/Pulmonology
LASW1835 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
PF-06410293 · Pfizer · Immunology
PF-06410293 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
CD0271 · Galderma R&D · Dermatology
CD0271 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.
GI148512 · GlaxoSmithKline · Respiratory / Immunology
GI148512 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
RPH-051 · R-Pharm · Immunology
RPH-051 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
LASW1510 · Almirall, S.A. · Immunology / Dermatology
LASW1510 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production in immune cells.
GW685698X · GlaxoSmithKline · Respiratory/Pulmonology
GW685698X is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
DFN-11 · Dr. Reddy's Laboratories Limited · Respiratory/Immunology
DFN-11 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by suppressing cAMP degradation in immune cells.
GSK5733584 · GlaxoSmithKline · Immunology
GSK5733584 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory signaling by increasing intracellular cAMP levels.
GSK1562902A · GlaxoSmithKline · Respiratory/Pulmonology
GSK1562902A is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.
GSK523338 · GlaxoSmithKline · Respiratory/Pulmonology
GSK523338 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.
MP513 · Handok Inc. · Respiratory/Pulmonology
MP513 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
GSK576428 · GlaxoSmithKline · Immunology
GSK576428 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels in immune cells.

Phase 2 pipeline (2)

AL8326 high dose group · Advenchen Pharmaceuticals, LLC. · Immunology/Respiratory
AL8326 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
GSK217744 · GlaxoSmithKline · Immunology
GSK217744 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.

Phase 1 pipeline (2)

ARQ-151 cream 0.15% · Arcutis Biotherapeutics, Inc. · Dermatology
ARQ-151 is a selective phosphodiesterase 4 (PDE4) inhibitor that modulates inflammatory responses.
Apremilast Modified Release 13 · Amgen · Immunology
Apremilast is a small molecule inhibitor of phosphodiesterase 4 (PDE4), which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP).